The deal provides immediate and certain cash value at a premium. Traders should monitor the arbitrage spread, which will narrow as the close approaches. Key risks include regulatory hurdles and potential competing bids, though no go-shop provision suggests a clean path. Look for the definitive proxy statement for detailed terms and voting timeline.
CPRX drugs
CPRX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 8 $31.15entry
- T+1 · 6mo ago 0.00%α −0.23% · $31.15
- T+5 · 6mo ago +0.03%α −1.43% · $31.16
- T+20 · 5mo ago +0.39%α +0.36% · $31.27
- T+60 · due 3mo ago Pending
Price Chart
How similar events traded
Executive Summary
Catalyst Pharmaceuticals (CPRX) filed additional proxy soliciting materials for its pending acquisition by Angelini Pharma for $31.50 per share in cash, representing a total equity value of approximately $4.1 billion. This all-cash deal offers a 21% premium to the unaffected closing price and a 28% premium to the 30-day VWAP, and has been unanimously approved by Catalyst's board. The transaction is expected to close in Q3 2026, subject to shareholder and regulatory approvals.
Key Financial Metrics
Key Facts
- Angelini Pharma acquires Catalyst for $31.50 per share in cash, total equity value ~$4.1 billion
- 21% premium to unaffected closing price on April 22, 2026; 28% premium to 30-day VWAP
- Catalyst Board unanimously approved; received fairness opinion from JP Morgan
- No go-shop provision; termination fee is typical and customary
- Expected close in Q3 2026, subject to shareholder vote and regulatory approvals
Financial Impact
$4.1 billion total equity value; $31.50 per share cash consideration representing 21-28% premium
Risk Factors
- Shareholder approval may face dissident votes; though board is unanimous
- Regulatory approvals, including antitrust clearance, could delay or block the transaction
- Termination fee may deter competing bids but does not eliminate them entirely
- Integration risk for Angelini Pharma as it establishes U.S. commercial presence
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-212474 |
| Document: 0001193125-26-212474-index-headers.html | 0001193125-26-212474 |
| Document: 0001193125-26-212474-index.html | 0001193125-26-212474 |
| Document: 0001193125-26-212474.txt | 0001193125-26-212474 |
Track record
16 reports on CPRX
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
- Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
- Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
- Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
- Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
- Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
- Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
- Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
- May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
- May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers